Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAA-T Cells With Nivolumab for Relapsed/Refractory Lymphoma
NCT03843294Phase 1Active, not recruiting
- Sponsor
- Catherine Bollard
- Start
- Jun 2019
- Primary completion
- May 2023
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Tumor-Associated Antigen-Specific T Cells in Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL), sponsored by Catherine Bollard. Primary endpoint: Incidence of Product-Emergent Adverse Events at 6 weeks. Started Jun 2019; status: active, not recruiting.
02
Drugs
Tumor-Associated Antigen-Specific T Cells
03
Conditions
Hodgkin lymphoma (HL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03843294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03843294.